Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
IMPORTANCE OF THE FIELD: Kidney plays a key role in the elimination of xenobiotics and metabolic products from the body, where renal clearance is determined by glomerular filtration, tubular secretion and reabsorption processes. The proximal tubule of the nephron is equipped with multi-specificity uptake and efflux transporters for the secretion of a broad range of xenobiotics, while the compound physicochemical space drives the tubular reabsorption. Due to involvement of transporters, renal clearance is possibly associated with renal drug-drug interactions (DDIs) in clinical situations. Nevertheless, renal insufficiency in diseased population is associated with altered transporter activity and evidently affects the pharmacokinetics of both renally and non-renally cleared compounds. Thus, early information on renal clearance is critical for successful development of compounds in certain chemical space. AREAS COVERED IN THIS REVIEW: This review provides updated information on the influence of physicochemical properties and the relevance of transporters in renal clearance and the associated drug interactions. In silico tools to predict the renal clearance at the discovery stage along with the potential alterations in drug disposition in the renal disease state are discussed with preclinical and clinical examples. WHAT THE READER WILL GAIN: The review provides comprehensive knowledge with recent examples to moderate renal disposition concerns in the drug discovery and development settings. TAKE HOME MESSAGE: Consideration of clearance pathways early in the discovery process has become critical for successful development of compounds. Although significant progress has been made in elucidating the physicochemical drivers and biochemical processes for this pathway, the predictive ability remains a challenge. Furthermore, development of renally cleared compounds should progress with a clear understanding of possible issues including transporter-mediated DDI and disease state.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular properties that influence the oral bioavailability of drug candidates
Veber, D. F., Johnson, S. R., Cheng, H.-Y., Smith, B. R., Ward, K. W., & Kopple, K. D. (2002) · Journal of Medicinal Chemistry · doi:10.1021/jm020017n · Cited by 8,420 · cited 1×
“These trends can be interpreted as the effect of permeability on passive reabsorption [20,21].”
BackgroundMembrane transporters in drug development
The International Transporter Consortium, Giacomini, K. M., Huang, S.-M., Tweedie, D. J., Benet, L. Z., Brouwer, K. L. R., Chu, X., Dahlin, A., Evers, R., Fischer, V., et al. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3028 · Cited by 3,340
To Scale or Not to Scale: The Principles of Dose Extrapolation
Sharma, V., & McNeill, J. H. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00267.x · Cited by 544 · cited 1×
“Renal blood flow and number of nephrons show good allometry and a simple allometric scaling of animal renal clearance is successful in predicting human renal clearance, especially for compounds primarily eliminated in urine by glomerular filtration [9,10].”
BackgroundEVALUATION OF DRUG-DRUG INTERACTION IN THE HEPATOBILIARY AND RENAL TRANSPORT OF DRUGS
Shitara, Y., Sato, H., & Sugiyama, Y. (2005) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.44.101802.121444 · Cited by 336 · cited 3×
“Due to transporter involvement, the secretion process is saturable and may be inhibited by co-administrated drugs leading to the possibility of clinical DDIs [14-16].”
BackgroundHosea, N. A., Collard, W. T., Cole, S., Maurer, T. S., Fang, R. X., Jones, H., Kakar, S. M., Nakai, Y., Smith, B. J., Webster, R., et al. (2009) · The Journal of Clinical Pharmacology · doi:10.1177/0091270009333209 · Cited by 300
Cited by
Heger, M., van Golen, R. F., Broekgaarden, M., & Michel, M. C. (2014) · Pharmacological Reviews · doi:10.1124/pr.110.004044 · Cited by 576
Predicting Clearance Mechanism in Drug Discovery: Extended Clearance Classification System (ECCS)
Varma, M. V., Steyn, S. J., Allerton, C., & El-Kattan, A. F. (2015) · Pharmaceutical Research · doi:10.1007/s11095-015-1749-4 · Cited by 334
Self-citationFan, J., & de Lannoy, I. A. M. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2013.09.007 · Cited by 309
Mathialagan, S., Piotrowski, M. A., Tess, D. A., Feng, B., Litchfield, J., & Varma, M. V. (2017) · Drug Metabolism and Disposition · doi:10.1124/dmd.116.074294 · Cited by 128
Self-citationIn Vitro–In Vivo Extrapolation Method to Predict Human Renal Clearance of Drugs
Kunze, A., Huwyler, J., Poller, B., Gutmann, H., & Camenisch, G. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.23851 · Cited by 48
Metadata
- Authors
- Feng, B., LaPerle, J. L., Chang, G., & Varma, M. V.
- Venue
- Expert Opinion on Drug Metabolism & Toxicology
- Publisher
- Informa UK Limited
- Published
- 2010-05-03
- Volume
- 6
- Issue
- 8
- Pages
- 939-952
- ISSN
- 1742-5255 (ISSN-L)
- 1744-7607
- OpenAlex
- W2154165320
- Cited by
- 105
- References
- 5
- FWCI
- 2.56
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. https://app.cochat.ai/papers/10.1517/17425255.2010.482930
- The paper
- Feng, B., LaPerle, J. L., Chang, G., & Varma, M. V. (2010). Renal clearance in drug discovery and development: molecular descriptors, drug transporters and disease state. Expert Opinion on Drug Metabolism & Toxicology. https://doi.org/10.1517/17425255.2010.482930
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.